Most Read Articles
03 Mar 2016
The Drug Control Authority (DCA) of Malaysia has approved a new indication for the long-acting somatostatin analogue lanreotide. This new indication is for the treatment of grade 1 and low grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)—of midgut, pancreatic or unknown origin except the hindgut—in adult patients with unresectable locally advanced or metastatic disease.

Infections predict death in diffuse large B cell lymphoma

16 Jul 2017
GIS, CSI make first collaborative discovery on cancer progression

Diffuse large B cell lymphoma (DLBCL) patients with neutropenia and multiple comorbidities have a high risk of death and infection, a new study reports. Moreover, infection is an independent predictor of survival.

In a cohort of 325 DLBCL patients, Charlson Comorbidity Index (CCI) scores of 3 to 5 (hazard ratio [HR], 2.16; 95 percent CI, 1.71 to 2.74; p<0.001) and ≥6 (HR, 3.91; 2.34 to 6.28; p<0.001) were significantly correlated with infections.

Having Eastern Cooperative Oncology Group (ECOG) scores of 1 (HR, 2.09; 1.46 to 3.01; p<0.001), 2 (HR, 3.33; 2.22 to 5.04; p<0.001) and 3 (HR, 3.36; 1.99 to 5.66; p<0.001), and neutropenia within 48 hours (HR, 2.46; 1.91 to 3.17; p<0.001) were also associated with increased risks of infection.

Over the study duration of 10 years, 99 deaths (30.5 percent) were reported. The median time from diagnosis to death was 273 (129 to 636) days. The most common cause of death was progressive lymphoma (58.6 percent), followed by infection (12.1 percent) and other cancers (5.5 percent).

CCI scores of 3 to 5 (HR, 4.34; 2.00 to 6.33; p<0.001) and ≥6 (HR, 7.36; 3.38 to 16.00; p<0.001), an ECOG status of 1 (HR, 2.61; 1.02 to 6.66; p=0.045) and 3 or 4 (HR, 7.16; 2.04to 25.06; p=0.002), and infection upon admission (HR, 3.27; 2.03 to 5.27; p<0.001) were all independent and significant predictors of survival.

Participants were recruited from Monash Health I Melbourne, Australia, and were receiving rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) or similar chemotherapies.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
03 Mar 2016
The Drug Control Authority (DCA) of Malaysia has approved a new indication for the long-acting somatostatin analogue lanreotide. This new indication is for the treatment of grade 1 and low grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)—of midgut, pancreatic or unknown origin except the hindgut—in adult patients with unresectable locally advanced or metastatic disease.